Peters S, et al. Nivolumab + low-dose ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non–small cell lung cancer: CheckMate-227 part 1 final analysis. ESMO Congress 2019, abstract LBA4.
AI-biomarker voor respons op atezolizumab-bevacizumab bij HCC
jan 2024 | Maag-darm-leveroncologie